Labeling error on popular drug poses potential health risks
The US Food and Drug Administration (FDA) has issued a voluntary recall of Clonazepam Orally Disintegrating Tablets due to a potentially life-threatening labeling issue. The recall, announced by pharmaceutical company Endo Inc., involves 16 lots of the drug commonly prescribed for anxiety and seizure disorders.
Dangerous labeling error discovered
The mislabeled products contain incorrect dosage strength information and a wrong National Drug Code on their packaging, errors attributed to a third-party packaging company. The FDA warned that patients taking an incorrect dose of Clonazepam could face severe side effects, including significant sedation, confusion, dizziness, diminished reflexes, ataxia (lack of muscle coordination), and hypotonia (reduced muscle tone).
“There is a reasonable probability for significant, possibly life-threatening, respiratory depression, especially for patients with concomitant pulmonary disease, patients with near-maximal prescribed dosing, and those taking other medications that may exacerbate respiratory depression,” the FDA stated.
No adverse effects reported so far
Endo Inc. clarified that as of November 21, no adverse events or health issues have been reported in connection with the recalled lots.
The FDA has advised consumers in possession of unused Clonazepam from the affected lots to stop using the medication immediately. Retailers and distributors have been instructed to cease distribution and sale of the recalled products.
“Distributors and retailers should immediately stop dispensing and return the affected lots to the place of purchase or contact Inmar,” the FDA noted.
Steps for affected consumers
Individuals who believe they may have taken an incorrect dose of Clonazepam are urged to contact their healthcare provider promptly. For additional information, consumers can contact Inmar Inc., the recall handler, at 855-589-1869 or via email at rxrecalls@inmar.com.
Background on Clonazepam
Clonazepam, commonly marketed under the brand name Klonopin, is a widely used anti-anxiety medication and anticonvulsant. However, its potency and potential for side effects make accurate dosage crucial to patient safety.
This recall underscores the importance of vigilance in pharmaceutical packaging and the critical need for accurate labeling to prevent potentially life-threatening outcomes.
